GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other EventsItem 8.01. Other Information
On December 20, 2016, GTx, Inc. (the “Company”) received a letter from the staff of The NASDAQ Stock Market LLC (“NASDAQ”) notifying the Company that the Company has regained compliance with the minimum $1.00 bid price per share requirement for continued listing on The NASDAQ Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously reported, NASDAQ had previously notified the Company of its noncompliance with the Bid Price Rule and on December 5, 2016, the Company effected a reverse stock split of its common stock, the primary purpose of which was to enable the Company to regain compliance with the Bid Price Rule. As a result of the Company regaining compliance with Bid Price Rule, NASDAQ has now closed this matter.
About GTx, Inc. (NASDAQ:GTXI)
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage. GTx, Inc. (NASDAQ:GTXI) Recent Trading Information
GTx, Inc. (NASDAQ:GTXI) closed its last trading session down -0.09 at 5.44 with 16,645 shares trading hands.
An ad to help with our costs